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CASE REPORT
A 41-year-old man, a former smoker (20 pack-years), was 
referred to Kyoto University Hospital, Kyoto, Japan, because of 
an abnormal chest shadow detected at an annual medical check-
up. Positron emission tomography revealed multiple metastases 
to both the liver and bone. A biopsy of the pulmonary nodule 
demonstrated adenocarcinoma. Combination chemotherapy 
with pemetrexed and carboplatin was started, but the disease 
progressed after six cycles of chemotherapy. He then received 
multilines of chemotherapy, including gemcitabine, bevaci-
zumab, erlotinib, TS-1, and docetaxel. Two years after the start of 
treatment, he developed multiple brain metastases and received 
whole-brain radiation therapy. At that time, molecular testing 
for echinoderm microtubule-associated protein like 4 (EML4)-
anaplastic lymphoma kinase (ALK) had just become com-
mercially available in Japan, and his tumor demonstrated ALK 
rearrangement (Fig. 1). Then crizotinib was started at a dose of 
250 mg twice daily. Abdominal computed tomography showed 
a marked decrease in the size of liver metastases, and magnetic 
resonance imaging of the brain demonstrated improvement of 
brain metastases; however, regrowth of brain metastases was 
detected 8 months after the start of crizotinib. Extracranial dis-
ease, including liver metastases, was under control with crizo-
tinib. We therefore decided to increase the dose of crizotinib 
after a thorough discussion. At first, the dose was escalated to 
750 mg/d. The dose was then escalated to 1000 mg/d after we 
confirmed that no new toxicities had occurred. Brain magnetic 
resonance imaging reassessed 2 weeks after the start of dose 
escalation demonstrated the striking improvement of multiple 
brain metastases; however, his brain diseases rapidly progressed 
after 1 month from the dose escalation (Fig. 2). After the dose 
escalation, he developed bradycardia without accompanying 
any symptoms. Pulse rate before and after the dose escalation 
were 50/minute and 39/minute, respectively.
DISCUSSION
Although it was reported that crizotinib is effective 
for brain metastases,1 its penetration into cerebrospinal fluid 
(CSF) is considered to be poor. Costa et al.2 measured the con-
centration of crizotinib in both CSF and plasma and reported 
that the CSF-to-plasma ratio of crizotinib was only 0.0026. 
Because of this relatively low drug exposure, the brain may 
be a site susceptible to progression in patients with ALK rear-
rangement and treated with crizotinib. A similar scenario has 
been observed also in patients with epidermal growth factor 
receptor (EGFR) mutation and treated with EGFR tyrosine 
kinase inhibitors, and the efficacy of high-dose gefitinib was 
reported in patients with EGFR mutation who developed brain 
metastases during treatment with a standard dose of gefitinib.3 
Recently, Gandhi et al.4 reported a patient who was effectively 
treated with high-dose pemetrexed and high-dose crizotinib 
in the same situation; however, the escalated dose of crizo-
tinib was only 100 mg/d, and the efficacy mainly seemed to 
be the result of pemetrexed. Therefore, we believe that this is 
the first case in which high-dose crizotinib was used alone for 
refractory brain metastases that developed during treatment 
with the standard dose of crizotinib. However, in this case, 
response duration was quite short and CSF concentration was 
not measured. In addition, 1000 mg/d of crizotinib is above the 
maximum tolerated dose. High-dose crizotinib cannot be rec-
ommended in routine clinical practice because safety data and 
efficacy are lacking in a prospective cohort. Further research 
is required in this setting.
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FIGURE 1. A, Fluorescent in situ 
hybridization showed translocation 
of ALK. B, Immunohistochemistry for 
ALK protein was strongly positive (3+). 
ALK, anaplastic lymphoma kinase.
A B C
FIGURE 2.  Brain magnetic reso-
nance imaging before and after high-
dose crizotinib treatment. A Before 
high-dose crizotinib. B, Two weeks 
after dose escalation. C, One month 
after dose escalation.
